Specifically, tumor cells can evade immunosuppression when exosome surface PD-L1 binds to the anti-PD-L1 antibody, leaving the tumor PD-L1 exposed, or when exosome surface PD-L1 binds to PD-1 on effector T cells during monoclonal antibody treatment (Chen et al., 2021). The gene discussed is CD274; the disease is neoplasm.